Small cell lung cancer (SCLC) is an aggressive illness, for which cytotoxic chemotherapy appears to have plateaued. A number of abnormal genetic events have been identified in SCLC, including overexpression of several receptor tyrosine kinases (RTKs). RTKs are proto-oncogenes, and are key regulators for cell growth, differentiation, survival or motility. The role of RTKs has just begun to be identified in SCLC and we would like to propose to study c-Met in particular. SCLC cell growth can be influenced in a paracrine fashion with receptors such as c-Met and its ligand hepatocyte growth factor (HGF) produced by stromal cells, c- Met/HGF has been shown to be involved in proliferation, cell motility and migration, invasion, angiogenesis and metastasis in other solid tumors. There are a considerable number of mutations identified for c-Met in a variety of solid tumors, however none to date have been investigated in lung cancer specimens. The best characterized mutations are in hereditary renal cell carcinoma and the mutations are mainly in the tyrosine kinase domains. We propose to study the role of c-Met in SCLC. Utilizing 10 separate SCLC cell lines and 32 paired tumor specimens from patients with SCLC, we have identified novel mutations in c-Met (3/10 cell lines and 4/32 tumor tissue samples), especially in the juxtamembrane (JM) domain. The specific JM domain mutations in c-Met have not been previously described in SCLC or other tumors. We have recently also shown the c-Met/HGF pathway to be functional in SCLC cell lines, with dramatic effects on cell motility and migration. The goal of this proposal is to determine the role of the mutations of c-Met in SCLC. Also, we will study the implications of c-Met/HGF activation in SCLC with emphasis on cell motility and migration as a reflection of metastasis of SCLC. Finally, we will utilize small molecule inhibitors that we have obtained of c- Met to determine if this pathway can be therapeutically targeted in SCLC with the eventual goal of bringing these molecules to clinical trials. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100750-03
Application #
7014510
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2004-03-01
Project End
2008-02-29
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
3
Fiscal Year
2006
Total Cost
$244,223
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Kawada, Ichiro; Hasina, Rifat; Arif, Qudsia et al. (2014) Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res 74:884-95
Sadiq, Ahad A; Salgia, Ravi (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089-96
Hasina, Rifat; Mollberg, Nathan; Kawada, Ichiro et al. (2013) Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res 73:184-94
Diamond, Jennifer R; Salgia, Ravi; Varella-Garcia, Marileila et al. (2013) Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol 31:e254-8
Morales La Madrid, Andres; La Madrid, Andres Morales; Campbell, Nicholas et al. (2012) Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol 7:199-210
Kanteti, Rajani; Krishnaswamy, Soundararajan; Catenacci, Daniel et al. (2012) Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer 51:841-51
Lukas, Rimas V; Nicholas, Martin Kelly; Villaflor, Victoria et al. (2012) Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. J Neurol Res 2:1-9
Doçi, Colleen L; Mankame, Tanmayi P; Langerman, Alexander et al. (2012) Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol 31:15-24
Sadiq, Ahad A; Salgia, Ravi (2012) Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol 7:S372-4
Surati, Mosmi; Patel, Premal; Peterson, Amy et al. (2011) Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 11:1655-62

Showing the most recent 10 out of 60 publications